
Press Releases

In the News


- Apr 26
Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)


- Apr 11
Ymmunobio Appoints New Chief Operating Officer

- Mar 8
Ymmunobio Accepted into Innosuisse Core Coaching

- Mar 2
Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board
- Feb 28
FDA Grants Orphan Drug Designation to Ymmunobio’s CEACAM Antibody for the Treatment of Liver Cancer


- Feb 16
Ymmunobio Appoints Dr. Caroline Germa to Board of Directors
- Feb 8
Ymmunobio Appoints Angela S. Gibbs as Chief Business Officer
- Jan 31
Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR antibodies
- Jan 10
Ymmunobio Appoints Dr. Michel Janicot as Chief Development Officer
- Oct 19, 2022
Ymmunobio selected by BIO-Europe to participate in its Start-up Spotlight Session
- Oct 13, 2022
Ymmunobio to Present Pre-Clinical Data at Annual Meeting of the Society for Immunotherapy of Cancer
- Jun 14, 2022
Ymmunobio Signs Collaboration Agreement with YUMAB
- Apr 5, 2022
Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH
- Jan 19, 2022
Ymmunobio AG announces appointment of Dr. Keith Skubitz